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Recently, mouse B cell hybridomas and plasmacytomas have been described
(1, 2) whose in vitro growth is strictly dependent on a mouse T cell-derived
factor provisionally designated interleukin-HP1 (IL-HP1) . This 22-29 kD pro-
tein, which was purified to homogeneity and partially sequenced, shows no
homology with known cytokines . Its relation to the P388-D1 macrophage line-
derived plasmacytoma growth factor (3) has not yet been defined . We have also
observed that thesupernatant ofhumanfibroblast cultures stimulated by double-
stranded RNA or IL-1 can sustain the growth of the IL-HP1-dependent hybri-
doma cell lines (4) . Both stimuli for this hybridoma growth factor (HGF) activity
are also known to be inducers of IFN-ß, (5) . However, since pure IFN-ß, was
devoid of HGF activity (4), we hypothesized that a substance coinduced with
IFN-ß, is responsible for the HGF activity . One such substance is a protein
termed 26 kD by some workers (6, 7) and IFN-ß2 by others (8) . Its IFN-like
antiviral activity, which has formed the basis for its denomination as IFN-ß2, is
rather weak, and this has raised the question of a possible other biological
function for this protein .
Materials and Methods
BriefDefinitive Report
Cell Cultures. B cell hybridomas were 6H8 (rat-mouse) and 7TD1 (mouse-mouse),
both dependent for their growth on the T cell-derived HGF, IL-HP1 (1), IL-HPI-
dependent mouse plasmacytoma lines were derived from TEPC 1033, MOPC 104E,
MOPC 173, and RPC 20, as described (2) .
Assay Systems. Antiviral activity of cytokines is expressed in antiviral units/ml
(AVU/ml) as determined on E6SM diploid fibroblasts or MG-63 osteosarcoma cells using
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a cytopathic effect reduction assay with vesicular stomatitis virus as a challenge virus (4).
The assay for HGF was performed by incubating 7TD1 or 6H8 cells with serial dilutions
ofgrowth factor and by colorimetric determination ofcell numbers (1). The plasmacytoma
growth activity was determined by measuring ['Hlthymidine incorporation (2).
Cytokines.
￿
Natural IL-1,B (22 kD factor) was obtained from Con A-stimulated PBL
and purified to homogeneity as described (9); recombinant DNA-derived IL-la, IL-1,8,
and TNF-a, produced in Escherichia coli, were obtained by courtesy of Prof. C. Dinarello,
Tufts University School of Medicine, Boston, MA (origin of IL-la, Genzyme Inc., Boston,
MA; origin of TNF-a, Genentech, San Francisco, CA).
Production of HGF.
￿
HGF was produced in MG-63 cells, induced with IL-1,8. The
supernatant fluid was processed through a five-step concentration and purification sched-
ule as follows: (a) batch adsorption to controlled pore glass (CPG) and desorption by acid;
(b) immuno-affinity chromatography using a polyclonal antibody against CPGpurified
HGF; (c) gel filtration on Ultro-gel AcA54 (LKB Produkter, Bromma, Sweden); (d) FPLC
on a cation exchange column (Mono S, Pharmacia Fine Chemicals, Uppsala, Sweden); (e)
reversed-phase HPLC on a C, 250 A pore size TSK TMS-250 column (LKB Produkter).
NH2-terminal sequence analysis was carried out on a gas phase sequencer (model 478;
Applied Biosystems, Inc., Foster City, CA) equipped with an on-line phenylthiohydantoin
analyzer (model 120A; Applied Biosystems, Inc.).
RNA-DNA Hybridization.
￿
DNA from the following plasmids were used: pBR322; p26K-
1, a pBR322 derivative containing a 737-bp cDNA sequence for 26K, originally isolated
by Haegeman et al. (7); and pAB48K-5, a pBR322 derivative containing a 1,021-bp cDNA
sequence for a human elongation factor la. 10 tag of CsCl-purified plasmid DNA was
denatured and applied to 1-cm2 nitrocellulose filters. After baking and washing, the filters
were shaken (3 h, 47 ° C) in hybridization buffer (500 Al) containing 40 Ag of RNA.
Residual unbound RNA (R), as well as RNA in two 500 Al washings (W, and W2; 10 min,
47°C) were collected. The plasmid-bound RNA was then eluted from the filters by
heating (1 min, 100°C) in 300 A1 distilled water containing 20 Ag/ml E. coli tRNA. The
eluate (E) was also collected. A fixed fraction of all collected fluids was used directly for
RNA/dot-blot assays against the 26K cDNA probe (a 480-bp Sau 3A cDNA fragment of
26K cDNA [7l, sp act - 1.9 x 109 cpm/wg); the remaining fraction was alcohol-precipitated.
The pellets were washed twice in 75% cold ethanol, redissolved in 50 (R), 10 (W, and
W2), and 5 Al (E) bidistilled water and used for injection in Xenopus oocytes (50 nl per
oocyte; 10 oocytes per RNA sample). After 48 h incubation culture fluids were collected,
supplemented with 10% FCS, and assayed for HGF activity.
Results and Discussion
Production of HGF by cells treated with various cytokines is documented by
Table I . Cultures of human diploid fibroblasts or MG-63 osteosarcoma cells were
treated with pure natural IL-1,6 or rIL-1 a, rIL-1fl, or rTNF-a, given at increasing
doses. Natural IL-I# was able to induce production of HGF by both cell types.
The minimum active doses of IL-1 required for significant induction were 0.1-
1 AVU/ml, and maximum production levels amounted to 104 to 104-4
U/ml
HGF activity. The HGF-inducing effect of natural IL-1,B was confirmed with
rIL-1,Q. In addition, IL-1 a was found to be equally potent and TNF-a less potent
as inducers of HGF in diploid fibroblasts. Control experiments indicated that
none of the cytokines had HGF activity by themselves.
A first type of evidence proving relatedness of IL-1-induced HGF to the 26
kD protein consisted in the demonstration that the mRNA for HGF binds to
immobilized 26 kD cDNA. Poly(A)+ RNA was extracted from MG-63 cell
monolayers that had been incubated for 6 h with 200 AVU/ml of IL-1,8. In four
of five consecutive experiments, Xenopus oocytes injected with this RNA secreted916
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TABLE I
Induction ofHGFby Stimulation ofDifferent Human Cell Lines by IL-1a, IL-10, and TNF-a
Confluent cell cultures (1.9 cm'; 0.5 ml) were incubated at 37°C for 2 h with medium (t2% FCS) containing IL-
1 or TNF-a, using duplicate sets for each indicated dose . The cultures were washed, replenished with plain
medium, and further incubated for 24 h . Supernatant medium was then harvested for HGF determination .
* Doses of cytokine are given in AVU/ml as assayed by antiviral effect on MG-63 cells; 1 U equals ^-1 ng.
x N, natural ; R, recombinant .
o Mean yield over 5 experiments ; in parentheses : standard error .
FIGURE 1 .
￿
Identification of 26 kD mRNA as HGF mRNA by hybrid-selected translation .
Poly(A)-rich RNA samples containing mRNA for HGF were obtained (5) from MG-63 cells
incubated for6 h with 200AVU/ml of IL-lß. Thesampleswere processed for hybrid selection
on three different filter-immobilized plasmid DNAs : p26K-1, pBR322, and pAB48K-5 . After
hybridization of the RNA to the filters, residual unbound RNA (R), as well as RNA in two
washings (W, and W2) were collected. The plasmid-bound RNA was then eluted (E) . Thefour
fractions (R,WI , Wa, and E) were then tested for the presence of HGFmRNA content by
translation in oocytes . In Exp. 1 the RNAfractions were also tested for the presence of 26 kD
cDNA sequence by dot-blot assay, using one-third dilution steps . HGF activity in the oocyte
supernatant is given as cell outgrowth numbers in percent of control cultures without HGF.
Each data set from Exp. 1 represents averages of two oocyte injection experiments . The HGF
activities from Exp. 2are averages from three oocyte injection experiments .
on average 30 U/ml/48 h of HGF activity against undetectable amounts in
controls receiving no RNA orRNA from untreated MG-63 cells . Samples of IL-
1-inducedHGFmRNA were processed for hybridizationto cloned 26 kD cDNA .
The results of these experiments are illustrated in Fig. 1, which shows analysis
of theRNA after enrichment on a 26 kD cDNA, both by dot-blot detection with
a 26 kD cDNA probe and by oocyte translation into HGF. Enrichment in 26 kD
mRNA sequences is clear from the comparison of the dot-blot pattern obtained
Inducing Yield of HGF (log,o U/ml) after stimulation with cytokine dose*
cytokinex Cell line
0 (control) 0.1 1 10 100 1,000
IL-10(N) E6SM 1.40(±0 .33)f 2.10(±0.45) 3.17(±0.19) 3.87(±0 .08) 4.40(±0.21) -
MG-63 2.38(±0.11) 2.76(±0.08) 3.26(±0.31) 3.81(±0.26) 3.94(±0.18) -
IL-10 (R) EeSM 2.2 2,9 2.9 3,4 4.7 -
IL-1a(R) EoSM <2.0 - 2.7 3.6 4.4 -
TNF-a (R) EfiSM <2.0 - 2.6 2.8 3.3 4.0VAN DAMME ET AL.
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FIGURE 2 .
￿
SDS-PACE of purified fibroblast-derived HPGF. A sample (2 1t1) of the peak
activity from reversed-phase HPLC wasrun on SDS-PAGE (15% gel) underreducing condi-
tionsandwas silver stained. The twohigh molecularmass bands in the test sample (bottom) are
staining artefacts.
TABLE 11
Growth-Promoting Activity ofFibroblast-derivedHGFforPlasmacytoma Cell Lines
Test material
Control
*Mean ±SE;n=4 .
Homogeneous HGF
(reversed-phase HPLC)
Control
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with RNA eluted from a 26 kD cDNA filter, with that obtained after elution
from filters containing pBR322 plasmids without 26 kD sequences. Concom
enrichment in HGF mRNA sequences is apparent from the fact that the RNA
eluted from 26 kD cDNA contained oocyte-translatable HGF mRNA while
similar RNA eluted from the filters carrying irrelevant DNAs scored negative in
the HGF assay . This concomitant adsorption to immobilized 26 kD cDNA of26
kD mRNA sequences and of HGF-translatable mRNA strongly supports the
contention of close relatedness between the two molecules .
More compelling evidence was obtained by purification to homogeneity and
sequence analysis of the naturally produced biologically active factor . The
supernatant fluid of IL-1-induced MG-63 cells was collected and processed
through a five-step concentration and purification schedule (see Materials and
Methods). The end product was shown to be electrophoretically homogeneous
as illustrated in Fig . 2 . The molecular mass of the pure protein was estimated at
24 kD and biological activity was eluted from gels at the same molecular mass
position . The pure protein (about 10 ug) was used for amino-acid sequence
analysis and the N142-terminal sequence was found to be as follows : ALA-PRO-
VAL-PRO-PRO-GLY-GLU-ASP-SER-LYS-ASP-VAL- . . . This sequence exactly
matches that predicted from the nucleic acid sequence of the 26 kD cDNA (7,
8) . The latter analysis also identifies the cleavage site between the signal peptide
(27 amino acids) and the mature protein .
That the human fibroblast-derived HGF could also act as a growth factor for
factor-dependent mouse plasmacytoma cell lines is documented by Table II .
Dilution
(-logo)
Plasmacytoma
TEPC 1085
cell growth
MOPC
104E
activity
MOPC
175
(cpm)
RPC20
3.0 50,500 58,600 17,900 26,600
3.7 5,800 4,500 4,100 1,000
4.4 100 650 1,100 150
5.1 100 250 100 100
100 200 450 100
3.0 26,983t 1182*
3.7 13,691 t 1676
4.4 217 t22
5.1 54t6
50t6918
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Partially as well as completely purified HGF supported the growth ofseveral of
those cell lines in a dose-dependent fashion.
It can be concluded that the IL-1-induced human fibroblast-derived hybri-
doma/plasmacytoma growth factor (HPGF) is identifiable as the 26 kD/IFN-Q2
protein with the possibility ofsome differences outside the NH2-terminal portion
ofthe molecule. Unlike IFN-,8,, the factor crosses the species barrier from man
to mouse, a phenomenon seen with various other cytokines (e.g., IL-1 and IL-
2). Furthermore, the factor is serologically related (4) to similar growth factors
from human leukocytes (1, 10). The portion of the NH2-terminal amino acid
sequence that is presently known (1) for the mouse T cell-derived HPGF (IL-
HP1) shows no significant degree of homology with the human fibroblast-
derived factor. However, this does not rule out the existence of homologous
regions elsewhere in the molecule.
With respect to the physiological target ofHPGF it should be mentioned that
all hybridoma and plasmacytoma growth factors discovered so far, seem to be
different from the classical B cell growth and differentiation factors, BSF-1 and
BCGF-II (1, 3). This was also the case for the HPGF described here, which, in
spite of its activity on murine plasmacytomas, had no effect in a murine BSF-1
assay.
The natural inducers of HPGF known so far are IL-1 and TNF-a. Both these
molecules have an antiviral effect on cells (5, 11), and this effect has been
postulated to be due to induction of either IFN-fl, (5) or 26 kD/IFN-N2 (11)-
Homogeneous preparations of natural HPGF (50 X 106 HGF U/ml) did not
show significant antiviral activity (<30 AVU/ml) in any of our assays in which
IL-I or TNF-a were antivirally active. The specific antiviral activity of HPGF
was <10' AVU/mg, allowing us to state that ifit were to be the mediator of the
antiviral effect of IL-1 or TNF, at least 10,000-fold more ofit would need to be
produced than if IFN-,B, (?108 AVU/mg) would be the mediator.
After submission of the present report, Hirano et al. (12) have published the
amino acid sequence of BSF-2. This sequence is identical to that of the 26 kD
protein, indicating that BSF-2 is also a growth factor.
Summary
A factor that promotes the growth of certain B cell hybridomas and of
plasmacytomas is shown to be produced by normal human fibroblasts and by a
line of human osteosarcoma cells (MG-63) after treatment with IL-1 or TNF.
The hybridoma-plasmacytoma growth factor (HPGF) is identified with a 26 kD
protein whose mRNA was previously shown to be induced in the same cells by
the same inducers. First, poly(A)-rich RNA extracted from IL-1-treated cells
could be enriched in HPGF-mRNA content by hybridization to 26 kD cDNA.
Second, MG-63-derived HPGF purified to electrophoretic homogeneity was
subjected to amino acid sequence analysis, whereby the NH2-terminal sequence
was found to match the nucleotide sequence ofa 26 kD cDNA clone.
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